CClinicalTrials.gg
CompletedNCT02330315Updated Apr 24, 2020

Effects of tDCS and tUS on Pain Perception in OA of the Knee

An interventional study of transcranial direct current stimulation (tDCS) and transcranial ultrasound (TUS) in Chronic Pain and Osteoarthritis, sponsored by Spaulding Rehabilitation Hospital. Completed at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2020-04-24.

Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to investigate the effects of transcranial direct current stimulation (tDCS) in conjunction with transcranial ultrasound (TUS) on pain perception and functional limitations in people with osteoarthritis of the knee. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.

02

Conditions studied

  • Chronic Pain
  • Osteoarthritis

Keywords

  • transcranial direct current stimulation
  • transcranial ultrasound
  • non-invasive brain stimulation
03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 28 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Spaulding Rehabilitation Hospital is the lead sponsor of 114 studies on the registry; 26 are open to participants now.

Of its 19 completed or terminated interventional studies of FDA-regulated products, 17 (89%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Able to provide informed consent to participate in the study.
  2. Subjects between 18-85 years old.
  3. Diagnosis of chronic osteoarthritis with pain of either the knee as self-reported.

    Prior to beginning baseline procedures this must be confirmed by medical records or a letter from the subject's physician. This document may either be brought in by the subject or retrieved by study staff after a medical release form is signed by the subject. After consent, if the subject fails to provide the necessary documentation or it cannot be retrieved by study staff the subject will be considered a screen fail.

  4. Existing knee pain in the past 6 months of at least 3 on a 0-10 VAS scale on average.
  5. Pain resistant to common analgesics and medications for chronic pain used as initial pain management such as Tylenol, Aspirin, Ibuprofen, Soma, Parafon Forte DCS, Zanaflex, and Codeine.
  6. Having the ability to feel pain as self-reported

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or trying to become pregnant in the next 6 months.
  2. History of alcohol or drug abuse within the past 6 months as self-reported.
  3. Contraindications to transcranial brain stimulation or TUS, i.e. implanted brain medical devices or implanted brain metallic devices.
  4. Unstable medical conditions (e.g. uncontrolled diabetes, uncompensated cardiac issues, heart failure or chronic obstructive pulmonary disease).
  5. Epilepsy.
  6. Use of carbamazepine within the past 6 months as self-reported.
  7. Suffering from severe depression (with a score of >30 in the Beck Depression Inventory)
  8. History of unexplained fainting spells as self-reported.
  9. Head injury resulting in more than a momentary loss of consciousness
  10. History of neurosurgery as self-reported.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Active tDCS + Active TUS

    Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).

    Device: transcranial direct current stimulation (tDCS) · Device: transcranial ultrasound (TUS)

  • Sham comparator
    Sham tDCS + Sham TUS

    Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).

    Device: transcranial direct current stimulation (tDCS) · Device: transcranial ultrasound (TUS)

Interventions

  • Devicetranscranial direct current stimulation (tDCS)

    Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.

  • Devicetranscranial ultrasound (TUS)

    Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.

06

What researchers measure

Primary outcomes

  1. Changes in Pain Scale

    Changes in the Visual Analogue Scale (VAS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound (applied in a diagnostic mode) is effective in reducing pain in subjects with osteoarthritis knee pain. The investigators will also look at changes in the Von Frey assessment and pain pressure threshold (PPT).

    Time frame: Measured for approximately 2 months

Secondary outcomes

  1. Changes in Mood

    The investigators will measure safety of tDCS and TUS by measuring changes in the Visual Analog Mood Scale (VAMS).

    Time frame: Measured for approximately 2 months

  2. Changes in cognition, attention, and focus

    The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition, attention, and focus with the California Computerized Assessment Package (CalCap) mini.

    Time frame: Measured for approximately 2 months

  3. Adverse Events

    At each session, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 5-point scale. The scale will also be administered at the follow-ups.

    Time frame: Measured for approximately 2 months

  4. Physical Examinations

    Trained study staff will perform standard physical examinations at several points throughout the study to ensure subject safety. Baseline findings will be compared to the findings observed at the various time points throughout the study to ensure there are no significant changes that may be study related.

    Time frame: Measured for approximately 2 months

  5. Single Leg Standing Balance Test

    The investigators will measure how long the subject can stand on one foot in order to measure any changes in balance

    Time frame: Measured for approximately 2 months

  6. Knee Proprioceptive Test

    Proprioceptive acuity will be assessed by the ability to reproduce passive positioning of the leg with eyes closed.

    Time frame: Measured for approximately 2 months

  7. Knee Extensor/Flexor Force Test

    The investigators will measure whether there are changes in knee extension/flexion abilities.

    Time frame: Measured for approximately 2 months

  8. Knee Range of Motion (ROM)

    The knee range of motion (flexion/extension angle) will be recorded with an electrogoniometer and motion analysis capture system.

    Time frame: Measured for approximately 2 months

  9. Step Test

    Subject will be asked to stand unsupported with the feet parallel to each other and a block 5 cm directly in front of them. Subject will then be advised which leg is the stepping leg and asked to place the whole foot onto the block, then return it fully down to the floor. This procedure will be repeated as fast as possible.

    Time frame: Measured for approximately 2 months

  10. Functional Reach Test

    The investigators will measure changes in subjects ability to complete the functional reach test across the duration of study.

    Time frame: Measured for approximately 2 months

  11. Timed Up and Go Test

    The investigators will measure if there are changes in the walking speed of the subject from the beginning of the study to the end.

    Time frame: Measured for approximately 2 months

  12. Changes in quality of life

    The investigators will use the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) to assess changes in quality of life and physical functioning.

    Time frame: Measured for approximately 2 months

  13. Neurological Examinations

    Trained study staff will perform standard neurological examinations at several points throughout the study to ensure subject safety. Baseline findings will be compared to the findings observed at the various time points throughout the study to ensure there are no significant changes that may be study related.

    Time frame: Measured for approximately 2 months

07

Study locations

1 site
  • Spaulding Rehabilitation Hospital
    Boston, Massachusetts 02129, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02330315
Lead sponsor
Spaulding Rehabilitation Hospital
Collaborators
Highland Instruments, Inc.
Responsible party
Felipe Fregni (Principal Investigator, Spaulding Rehabilitation Hospital) — Principal investigator
First posted
Jan 1, 2015
Start date
Mar 2015
Primary completion
Jun 2016
Completion
Aug 2016
Last update
Apr 24, 2020

Study contacts

Timothy Wagner, PhD
principal investigator · Highland Instruments, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion